
Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial
Author(s) -
Alexander Swanton,
Antony D. Lighten,
Ingrid Granne,
Enda McVeigh,
Stuart Lavery,
Geoffrey Trew,
Alon Talmor,
Nick RaineFenning,
Kannamannadiar Jayaprakasan,
T Child
Publication year - 2011
Publication title -
human reproduction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.446
H-Index - 226
eISSN - 1460-2350
pISSN - 0268-1161
DOI - 10.1093/humrep/der120
Subject(s) - polycystic ovary , metformin , ovarian hyperstimulation syndrome , live birth , medicine , gynecology , pregnancy rate , randomized controlled trial , pregnancy , placebo , ovary , obstetrics , endocrinology , in vitro fertilisation , biology , obesity , diabetes mellitus , insulin resistance , alternative medicine , pathology , genetics
Women with ovaries of polycystic morphology (PCO), without any other features of polycystic ovary syndrome (PCOS), respond similarly to women with PCOS when stimulated with exogenous gonadotrophins, and both groups share various endocrinological disturbances underlying their pathology. In women with PCOS, metformin co-treatment during IVF has been shown to increase pregnancy rates and reduce the risk of ovarian hyperstimulation syndrome (OHSS). The aim of this study was to investigate whether metformin co-treatment before and during IVF can also increase the live birth rate (LBR) and lower severe OHSS rates for women with PCO, but no other manifestations of PCOS.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom